Demonstrates improved treatment outcomes in high-risk acute myeloid leukemia, suggesting effective therapy.
To the editorCPX-351 is a liposomal encapsulation that delivers daunorubicin and cytarabine in a 1:5 drug ratio to leukemic cells. The effectiveness of CPX-351 in achieving better treatment outcome...
No takes yet. Share an insight, caveat, or question.
Onaka et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: